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OBJECTIVES: Minimising post-surgery length of stay is impor-
tant to patients, clinicians and payers who want to optimise
recovery rates and minimise costs. However, evaluating new
products and procedures using actual length of stay is inﬂuenced
by hospital payment incentives, organisational structures and
socio-economic factors. This study aimed to identify instruments
to measure post-anaesthesia home readiness and evaluate their
suitability for use in a clinical trial. METHODS: A literature
review was carried out to identify published evidence including
home readiness instruments. Medline, Embase and Biosis data-
bases were searched for RCTs and instrument-speciﬁc publica-
tions. The internet was searched for health technology
assessments, economic evaluations and guidelines. An inventory
of instruments was compiled and, for each, the suitability of use
in a clinical trial setting was assessed in terms of previous
examples of use in a clinical trial, evidence of validation and
reliability, compatibility with other recovery measures, support-
ing information and application to an in-patient setting.
RESULTS: Fifteen papers provided evidence of the use of the
Post-Anaesthetic Discharge Scoring System (PADS) [1] in a
variety of trial settings and validation work. Nine papers referred
to other instruments measuring home readiness but no other
instrument had been used in more than one trial or validated.
The British Association of Day Surgery referred to PADS in their
published guidelines. There was an example of PADS in an
economic evaluation of fast-tracking recovery [2]. CONCLU-
SIONS: PADS was found to be the most appropriate instrument
for assessing home readiness as it has undergone more validation
than other identiﬁed measures and there is evidence of its use
in multiple RCTs. [1] Chung et al. A post-anesthetic discharge
scoring system for home readiness after ambulatory surgery. J
Clin Anesth 1995;7:500–6; [2] Song et al. Fast-tracking (by-
passing the PACU) does not reduce nursing workload after
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OBJECTIVES: In acute pain studies, subjects are asked to report
on symptoms at speciﬁc intervals after dosing. One or more
assessments are often primary endpoints. When timed assess-
ments are collected on paper the actual time the assessments
were completed is unknown, and enforcing completion of the
assessment at a speciﬁc time is impossible. Electronic patient
reported outcome technologies (ePRO) allow control over the
window in which a subject can complete the electronic diary
(e-Diary), and a time stamp associated with diary completion.
E-Diaries assure the investigator of more reliable information:
the 120 minute assessment was completed at or near 120
minutes. But is there a down side? With a restricted window of
time for completing an e-diary in the acute pain model, how
compliant will subjects be? METHODS: Diary completion was
examined in 12 randomized clinical trials using the acute pain
model. Indications were surgical pain, migraine, or break
through pain. Subjects completed pain diaries at timed intervals
after dosing. In 4 trials, subjects completed at least some of the
assessments in the clinic or post surgical area allowing com-
parison of compliance in supervised settings to compliance with
e-diaries at home. Frequency of the assessments varied across the
trials, allowing some description of factors which may inﬂuence
compliance. Finally, design features, like a reminder alarm, were
correlated with time of diary compliance to understand the
usefulness of these features. RESULTS: e-Diary compliance in
supervised setting can be as high as 100%. Compliance in unsu-
pervised settings is typically 80%, although frequent assessments
correspond with decreased compliance. In one study that re-
quired extensive frequent assessments, e-Diary compliance is
much lower. Indication does not correlate with e-Diary compli-
ance in unsupervised settings. CONCLUSIONS: Factors that
correspond with e-diary compliance are supervision, frequency
and overall demand on subjects.
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OBJECTIVES: The study objective was to estimate health status
changes using the EuroQol (EQ-5D) in immune thrombocy-
topenia purpura (ITP) patients treated with romiplostim in two,
24-week randomized placebo controlled phase 3 trials.
METHODS: The EQ-5D was scored from 0 to 1 for both the
summary score (Index) and the visual analog scale (VAS) and was
given at baseline and every four weeks thereafter. Patients
received either romiplostim (titrated to maintain platelets
between 50 to 200 ¥ 109/L) or placebo at a 2:1 ratio. One trial
was conducted in patients (n = 62) with ITP without splenectomy
and the other was among patients (n = 63) refractory to splenec-
tomy. We pooled data across studies and evaluated the EQ-5D
change from baseline to week 24. We compared romiplostim
with placebo, as well as responders with non-responders.
Responders had mean platelet counts 50 ¥ 109/L for 6 of the
last 8 weeks on the study (regardless of treatment group). Effects
were estimated using linear regression (ﬁnal score as the depen-
dent variable adjusting for baseline score). Responder analyses
incorporated age and gender as covariates. Missing follow up
data were imputed using the last available value, unless a subject
died, in which case zero was imputed. Patients with insufﬁcient
data were excluded (n = 11). RESULTS: At baseline the median
age was 52 years (range 21 to 88), 65% were females, 82% were
white, and the mean platelet count was 16.5 ¥ 109/L. The differ-
ences in mean change from baseline for romiplostim compared
to placebo was 0.06 for the Index (p = 0.017) and 0.05 for VAS
(p = 0.040). Adjusted mean changes were similar for responders
versus non-responders (0.06 and 0.10 for the Index and VAS,
p < 0.05). CONCLUSIONS: Romiplostim use was associated
with signiﬁcant improvement in health status. Furthermore, these
results will be useful for assessing the value of romplostim in
economic models.
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OBJECTIVES: As obesity becomes a global epidemic, the use
of weight loss medications (WLM) continues to increase. The
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